Erratum (DOI:10.1016/j.nurpra.2007.08.022);Treatment of Adult HIV Infection: Antiretroviral Update and Overview

Journal for Nurse Practitioners

Volumn 3, Issue 9, 2007, Pages 612-624

  Orsega, Susan ^a  

^a NONE

Author keywords

Adherence; antiretroviral therapy; fusion inhibitors; HIV management; HIV AIDS; non nuclease reverse transcriptase inhibitors; nuclease reverse transcriptase inhibitors; protease inhibitors

Indexed keywords

EID: 35148827436     PISSN: 15554155     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurpra.2007.10.009     Document Type: Erratum

References (29)

1. Joint United Nations Programme on HIV/AIDS (UNAIDS). 2006 Report on the global AIDS epidemic (2006), UNAIDS, Geneva, Switzerland. Available at: www.unaids.org/en/hiv_data/2006globalreport/default.asp Accessed April 20, 2007.
2. Hammer S., Katzenstein D., Hughes M., et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. N Engl J Med 335 15 (1996) 1081-1090
3. Palella F., Delaney K., Moorman A., et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 338 13 (1998) 853-860
4. Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents (2006), Department of Health and Human Services, Rockville, MD
5. Hammer S., Saag S., Schechter M., et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 296 7 (2006) 827-843
6. Anderson V., and Orsega S. In: Edmunds M., and Mayhew M. (Eds). Pharmacology for the Primary Care Provider. 2nd ed. (2004), Elsevier Mosby, St Louis, MO 710-720
7. Flexner C. In: Brunton L., Lazo J., and Parker K. (Eds). Goodman and Gillman's The Pharmacological Basis of Therapeutics. 11th ed. (2006), McGraw Hill, New York, NY 1280-1310
8. Fauci A., and Lane H. In: Kasper D., Fauci A., Longo D., Braunwald E., Hauser S., and Jameson J. (Eds). Harrison's Principles of Internal Medicine. 16th ed. (2005), McGraw Hill, New York, NY 1123-1139
9. Peyriere H., Reynes J., Rouanet I., et al. Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J Acquir Immune Defic Syndr 35 3 (2004) 269-273
10. Gallant J., Staszewksi S., Pozniak A., et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients. JAMA 292 2 (2004) 191-201
11. Morse C., and Kovacs J. Metabolic and skeletal complications of HIV infection. JAMA 296 7 (2006) 844-854
12. Aberg J., Gallant J., Anderson J., et al. Primary care guidelines for the management of persons infected with human immunodeficiency virus; recommendations of the HIV medicine association of the Infectious Diseases Society of America. Clin Infect Dis 39 5 (2004) 609-629
13. Kopp J., Miller K., Mican J., et al. Crystalluria and urinary tract abnormalities with indinavir. Ann Intern Med 127 2 (1997) 119-125
14. Lalezari J., Henry K., O'Hearn M., et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 348 22 (2003) 2175-2185
15. Penny MA, Boucher M, Man M, et al. Pharmacogenetic analysis of polymorphisms in chemokine receptors CCR5 and CCRT with respect to safety and tolerance of maraviroc (abstract H-1099). Presented at the 45th Interscience Conference of Antimicromobial Agents and Chemotherapy, December 16-19, 2005, Washington, DC.
16. Osterberg L., and Blaschke T. Adherence to medication. N Engl J Med 353 5 (2005) 487-497
17. Baylor M., and Johann-Liang R. Hepatoxicity associated with nevirapine use. J Acquir Immune Defic Syndr 35 5 (2004) 538-539
18. Sanne I., Mommeja-Marin H., Hinkle J., et al. Severe hepatoxicity associated with nevirapine use in HIV infected subjects. J Infect Dis 191 6 (2005) 825-829
19. Eron Jr. J., Yeni P., Gathe Jr. J., et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomized non-inferiority trial. Lancet 368 9534 (2006) 476-482
20. Malan N, Krantz E, David N, et al. Efficacy and safety of atazanavir-based therapy in antiretroviral naive HIV-1 infected subjects, both with and without ritonavir: 48 week results from AI424-089 (abstract 107LB). Presented at the 13th Conference on Retrovirus and Opportunistic Infections, February 5-8, 2006, Denver, CO.
21. Robbins G., De Gruttola V., Shafer R., et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 349 18 (2003) 1850-1861
22. DeJesus E., Herrera G., Teofilo E., et al. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin Infect Dis 39 7 (2004) 1038-1046
23. Kottilil S., Polis M., and Kovacs J. HIV infection, hepatitis C infection, and HAART: hard clinical choices. JAMA 292 2 (2004) 243-250
24. Fundaro C., Genovese O., Rendeli C., et al. Myelomeningocele in a child with intrauterine exposure to efavirenz. AIDS 16 2 (2002) 299-300
25. Food and Drug Administration. FDA/Bristol Myers Squibb Issues Caution for HIV Combination Therapy with Zerit and Videx in Pregnant Women (January 5, 2001), US Department of Health and Human Services, Rockville, MD Talk Paper T01-02.
26. Miller K., Cameron M., Wood L., Dalakas M., and Kovacs J. Lactic acidosis and hepatic steatosis associated with the use of stavudine: a report of four cases. Ann Intern Med 133 3 (2000) 192-196
27. Hitti J., Frenkel L., Stek A., et al. For the PACTG 1022 Study team. Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022. J Acquir Immune Defic Syndr 36 3 (2004) 726-772
28. Sterne J., Hernan M., Ledergerber B., et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet 366 9483 (2005) 378-384
29. Mellors J., Munoz A., Giorgi J., et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 126 12 (1997) 946-954